ConductScience.org, home

Paper32199724

Accelerating the development of innovative cellular therapy products for the treatment of cancer.

Stewart MD and 16 others. Cytotherapy, 2020. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Accelerating the development of innovative cellular therapy products for the treatment of cancer. Papers, record 32199724. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32199724

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Accelerating the development of innovative cellular therapy products for the treatment of cancer.
PubMed
Journal
Cytotherapy
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.26
iCite
Revised in PubMed
2020-10-27
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stewart MDMark D
2Keane AAnne
3Butterfield LHLisa H
4Levine BLBruce L
5Thompson BBruce
6Xu YYuan
7Ramsborg CChris
8Lee AAnn
9Kalos MMichael
10Koerner CChin
11Moore TTimothy
12Markovic IIngrid
13Lasiter LLaura
14Ibrahim RRamy
15Bluestone JJeffrey
16Sigal EEllen
17Allen JJeff

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cell- and Tissue-Based TherapyMajor topic
Immunotherapy, AdoptiveMajor topic
NeoplasmsMajor topic
Therapies, InvestigationalMajor topic
Child
Combined Modality Therapy
Humans
Parents
Patient Safety
United States
United States Food and Drug Administration

Source PubMed

Download CSV of topics

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42464296Advanced herbal self-assembled nanoplatforms: targeted, stimuli-responsive, and precision therapeutics for human diseases.J Nanobiotechnology2026https://conductscience.org/library/papers/42464296PubMed
40937560Ursolic acid: A natural pentacyclic triterpenoid with clinical promise in gynecological and breast cancers (Review).Oncol Rep2025https://conductscience.org/library/papers/40937560PubMed
38077331Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations.Front Immunol2023https://conductscience.org/library/papers/38077331PubMed
36329460Sepax-2 cell processing device: a study assessing reproducibility of concentrating thawed hematopoietic progenitor cells.J Transl Med2022https://conductscience.org/library/papers/36329460PubMed
35606815The future of cancer immunotherapy for brain tumors: a collaborative workshop.J Transl Med2022https://conductscience.org/library/papers/35606815PubMed
33833444Industrializing engineered autologous T cells as medicines for solid tumours.Nat Rev Drug Discov2021https://conductscience.org/library/papers/33833444PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32199724

GET https://conductscience.org/api/papers/v1/32199724/authors